Approval · Notice of Compliance 25622 · 2021
AMLODIPINE: Notice of Compliance 25622
Issued April 9, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25622
- Date
- April 9, 2021
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Labelling update to match licensor
- Canadian reference product
- NORVASC (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AMLODIPINE | Not yet assigned | — |
Medicinal ingredients
- AMLODIPINE 2.5 MG per TAB
- AMLODIPINE 5 MG per TAB
- AMLODIPINE 10 MG per TAB